comparative evaluation of whole body and hepatic insulin resistance using indices from oral glucose tolerance test in morbidly obese subjects with nonalcoholic fatty liver disease比较评估的整个身体和肝胰岛素抵抗指数在病态肥胖受试者口服葡萄糖耐量试验与非酒精性脂肪肝病.pdfVIP

Hindawi Publishing Corporation Journal of Obesity Volume 2010, Article ID 741521, 7 pages doi:10.1155/2010/741521 Clinical Study Comparative Evaluation of Whole Body and Hepatic Insulin Resistance Using Indices from Oral Glucose Tolerance Test in Morbidly Obese Subjects with Nonalcoholic Fatty Liver Disease Kamran Qureshi,1 Ronald H. Clements,2 Fahad Saeed,3 and Gary A. Abrams4 1 Department of Medicine, University of Illinois at Urbana, Champaign, IL 61801, USA 2 Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294-1150, USA 3 Department of Medicine, University of Illinois at Urbana, Champaign, USA 4 School of Medicine, UAB Health Center at Montgomery, 2055 East South Blvd, Marrow Tower, Suite 806, Montgomery, AL 36116, USA Correspondence should be addressed to Gary A. Abrams, gabrams@baptistfi Received 9 November 2009; Revised 22 March 2010; Accepted 2 April 2010 Academic Editor: Basil J. Ammori Copyright © 2010 Kamran Qureshi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Nonalcoholic Fatty Liver Disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is a marker of Insulin Resistance (IR). Euglycemic-hyperinsulinemic clamp is the gold standard for measuring whole body IR (hepatic + peripheral IR). However, it is an invasive and expensive procedure. Homeostasis Model Assessment Index for Insulin Sensitivity (HOMA-IS), Quantitative Insulin Sensitivity Check Index (QUICKI) for hepatic IR and Insulin Sensitivity Index (ISI0,120 ), and Whole Body Insulin Sensitivity Index (WBISI) for whole body IR are